NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
0.5810
-0.0810 (-12.24%)
At close: Feb 12, 2026, 4:00 PM EST
0.5800
-0.0010 (-0.17%)
After-hours: Feb 12, 2026, 8:00 PM EST
Company Description
NovaBay Pharmaceuticals, Inc. manufactures and sells wound care products.
The company offers hypochlorous acid for use in the cleansing and irrigation of post-surgical wounds, minor burns, and superficial abrasions.
It sells its products to its distribution partners in China. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
NovaBay Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2000 |
| IPO Date | Oct 26, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Michael Kazley |
Contact Details
Address: 2000 Powell Street, Suite 1150, eleventh floor Emeryville, California 94608 United States | |
| Phone | 510 899 8800 |
| Website | novabay.com |
Stock Details
| Ticker Symbol | NBY |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001389545 |
| CUSIP Number | 66987P201 |
| ISIN Number | US66987P4090 |
| Employer ID | 68-0454536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Kazley | Chief Executive Officer and Director |
| Tommy Law | Controller, Interim Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2026 | 8-K | Current Report |
| Feb 10, 2026 | DEF 14A | Other definitive proxy statements |
| Jan 30, 2026 | 8-K | Current Report |
| Jan 30, 2026 | PRE 14A | Other preliminary proxy statements |
| Jan 29, 2026 | SCHEDULE 13D/A | Filing |
| Jan 28, 2026 | 8-K | Current Report |
| Jan 27, 2026 | D | Notice of Exempt Offering of Securities |
| Jan 21, 2026 | SCHEDULE 13D/A | Filing |
| Jan 21, 2026 | SCHEDULE 13D/A | Filing |
| Jan 20, 2026 | 8-K | Current Report |